UnitedHealth Raises Guidance, But Recovery Still Volume-Challenged

What happened

UnitedHealth Group raised 2026 adjusted EPS guidance to $19.50-$20.00, citing strong margin discipline, AI efficiencies, and Optum growth, per a bullish Seeking Alpha article. The article reaffirms a Buy rating, emphasizes an A+ credit rating, and touts a 2.4% dividend yield, framing the company as a quality dividend play. However, the latest DeepValue master report maintains a WAIT rating, arguing the recovery narrative is crowded and the stock at $408.70 already prices in sustained repair. The report notes that recent earnings strength leaned on $860M favorable reserve development, while revenue, membership, and Optum volumes contracted. Consequently, the article's upbeat tone contrasts with underlying fundamentals that still require proof of organic recovery and membership stabilization.

Implication

The new guidance raise does not alter the fundamental picture because earnings quality remains mixed, with reliance on reserves and cost actions. The stock trades at 26.3x earnings, leaving little room for execution missteps. Key checkpoints include 3Q/4Q26 MCR versus the 88.1% guide, AEP 2027 MA enrollment trends, and Optum Health volume stabilization. If those metrics improve without reserve support, the thesis could upgrade; if not, downside risk is substantial. Current holders may trim above $445, while new buyers should await a better entry or clearer proof of durable recovery.

Thesis delta

The new article is incrementally positive, reaffirming a Buy and raising EPS guidance, but this was largely known and already reflected in our WAIT rating. The article emphasizes dividend safety and balance sheet strength, which we acknowledge, but it understates volume erosion and reserve dependence. Therefore, no thesis change: we remain WAIT with attractive entry at $365 and trim above $445.